ISSCR News
ISSCR Launches Website to Inform Patients and the Public About Stem Cells
“The ISSCR has a long history of sharing scientifically validated information about the potential of stem cell research and clinical advances with the public,” said Amander T. Clark, ISSCR President. “Our reimagined website, AboutStemCells.org, gives us an important avenue to educate the public about the importance of our work, combat misinformation, and raise awareness for the dangers of using unproven and unapproved stem cell-based treatments.”
The ISSCR Introduces “Checklist” to Promote Global Best Practices for Human Stem Cell Research
Recommendations from the Standards for the Use of Human Stem Cells in Research, published in June by the International Society for Stem Cell Research (ISSCR), include a publishing “checklist” that is now being used by laboratory scientists and implemented in the review process by scientific publishers.
The ISSCR Statement on New Research with Embryo Models
The ISSCR supports research with embryo models derived from human pluripotent stem cells that is conducted with scientific and ethical rigor. ISSCR encourages researchers to continue to follow the ISSCR Guidelines for Stem Cell Research and Clinical Translation when considering research in this emerging area. Recent work presented at the ISSCR 2023 Annual Meeting in Boston, USA this month and additional research posted online as preprints shortly thereafter highlights the rapid pace of progress in the development of stem cell-based embryo models. To aid public understanding of this progress and assist the media in accurate reporting, the ISSCR provides the following information.
Improving potential stem cell-based treatments for patients with Type 1 Diabetes
Following encouraging results from pre-clinical research and a recent clinical trial on stem cell-based treatments for patients with Type 1 diabetes, researchers are now working on maximizing the function and potential of stem cell-based treatments for future application in patients.
The ISSCR Files Amicus Brief Supporting FDA’s Authority to Regulate Unproven Stem Cell-Based Interventions
The International Society for Stem Cell Research (ISSCR) filed an amicus curiae brief today to support the U.S. government’s appeal in U.S. v. California Stem Cell Treatment Center, Inc., a case that ruled the Food and Drug Administration (FDA) cannot regulate dangerous unproven stem cell-based interventions.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .